NET SALES ROSE 54% TO MSEK 37.1 IN THE THIRD QUARTER

THIRD QUARTER OF 2014
• NET SALES amounted to MSEK 37.1 (24.1).
• OPERATING PROFIT totalled MSEK 9.0 (4.5).
• PROFIT AFTER TAX amounted to MSEK 7.1 (3.7).
• PROFIT AFTER TAX PER SHARE was SEK 0.77 (0.41).
•CASH FLOW amounted to MSEK 3.3 (4.2).


ACCUMULATED 2014
• NET SALES amounted to MSEK 95.3 (76.1).
• OPERATING PROFIT totalled MSEK 20.5 (15.1).
• PROFIT AFTER TAX amounted to MSEK 16.4 (12.4).
• PROFIT AFTER TAX PER SHARE was SEK 1.80 (1.36).
•CASH FLOW amounted to MSEK 6.3 (4.1). Probi paid dividends of MSEK 6.8 (6.8).


SIGNIFICANT EVENTS DURING THE THIRD QUARTER:
• Probi and Pharmavite expanded their partnership in the US and in international
markets.
• NBTY launched products based on Probi Digestis® in the US retail market.
• Another trial confirmed that Probi’s probiotics can increase iron absorption
in women of child-bearing age.
• Vifor launched Probi Defendum® in Switzerland.
• An agreement was signed with Metagenics to launch Probi Defendum® in North
America.


SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD:
•Probi signed a distribution agreement with Laboratório Daudt for the launch of
Probi Digestis® in Brazil.


CEO’S COMMENTS:
“The third quarter was by far our best quarter ever. Net sales of MSEK 37.1
correspond to year-on-year growth of 54%. Our growth up to the third quarter was
25% and we are growing with increased profitability. The operating margin for
the reporting period is slightly higher than in 2013. As in recent quarters,
growth is attributable to the Consumer Healthcare business area where net sales
have risen 53% to date this year, compared with the corresponding period in
2013. This growth was primarily driven by successful launches conducted jointly
with our partners in the North American and South Korean markets. Due to strong
global demand for our products, we are now reviewing the organisation to ensure
we have the resources needed to seize the market opportunities in both of our
business areas in coming years,” says Peter Nählstedt, CEO of Probi.


INVITATION TO TELECONFERENCE (SWEDISH):
Time: Wednesday, 29 October 2014 at at 10.00 a.m. Phone number: +46 (0)8-519 99
030 Participants from Probi: Peter Nählstedt, CEO and Niklas Brandt, CFO. The
presentation is available at: www.probi.se and www.financialhearings.com

FOR FURTHER INFORMATION, PLEASE CONTACT:
Peter Nählstedt, CEO Probi, tel: +46 (0)46-286 89 23 or +46 (0)723-86 99 83, e
-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO Probi, tel: +46 (0)46-286 89 26 or +46 (0)706-62 98 83, e
-mail: niklas.brandt@probi.se


This information is such that Probi AB is required to disclose in accordance
with the Swedish Securities Market Act and/or the Financial Instruments Trading
Act.
The information was submitted for publication on 29 October 2014 at 8:45 a.m.


This is a translation of the Swedish version of the interim report. When in
doubt, the Swedish wording prevails.


ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops
effective and well-documented probiotics. Through its world-leading research,
Probi has created a strong product portfolio in the gastrointestinal health and
immune system niches. Probi’s products are available to consumers in more than
30 countries worldwide. Probi’s customers are leading food, health-product and
pharmaceutical companies in the Functional Food and Consumer Healthcare
segments. In 2013, Probi had sales of MSEK 102. The Probi share is listed on
NASDAQ OMX Stockholm, Small Cap. Probi has about 3,500 shareholders. Read more
at www.probi.se.